SELLAS Life Sciences Group, Inc.

SLS

US81642T2096

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
1.14 ^USD	+4.59%		-3.39%	+7.55%

16/07	Sellas Life Sciences' Potential Leukemia Treatment Receives Second Rare Pediatric Disease Designation	MT
08/07	Sellas Life Sciences' Potential Myeloid Leukemia Therapy Receives EU Orphan Drug Designation	MT

SELLAS Life Sciences Group, Inc.(NasdaqCM:SLS) added to S&P TMI Index

January 02, 2018 at 10:30 am IST

SELLAS Life Sciences Group, Inc. will be added to the S&P TMI Index

Latest news about SELLAS Life Sciences Group, Inc.

Sellas Life Sciences' Potential Leukemia Treatment Receives Second Rare Pediatric Disease Designation	16/07	MT
Sellas Life Sciences' Potential Myeloid Leukemia Therapy Receives EU Orphan Drug Designation	08/07	MT
SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia	08/07	CI
SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia	24/06	CI
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia	17/06	CI
SELLAS Life Sciences Group, Inc. Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML	10/06	CI
Certain Common Stock of SELLAS Life Sciences Group, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.	19/05	CI
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	01/05	CI
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	29/04	CI
North American Morning Briefing : Powell Awaited -2-	03/04	DJ
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Transcript : SELLAS Life Sciences Group, Inc. - Special Call	26/03
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML	26/03	CI
Sector Update: Health Care Stocks Ease Late Afternoon	16/03	MT
Top Midday Decliners	15/03	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	15/03	MT
Sellas Life Sciences Launches $20 Million Direct Offering, Private Placement -- Shares Fall	15/03	MT
SELLAS Life Sciences Group, Inc. announced a financing transaction	15/03	CI
SELLAS Life Sciences Group, Inc. Announces Executive Changes	08/03	CI
SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients	09/01	CI
Top Midday Decliners	05/01	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Thursday as Traders Mull Fed Meeting Minutes	04/01	MT
SELLAS Life Sciences Plans Public Offering of Stock, Warrants; Shares Drop Premarket	04/01	MT
SELLAS Life Sciences Group, Inc. announced that it expects to receive $8.999813 million in funding	04/01	CI

Chart SELLAS Life Sciences Group, Inc.

Duration

Period

More charts

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.14 USD

Average target price

5.833 USD

Spread / Average Target

+411.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SELLAS LIFE SCIENCES GROUP, INC.	+7.55%	65.84M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+23.73%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-15.68%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs